Johnson & Johnson said on Friday that its single-dose vaccine was 66 per cent effective in preventing COVID-19 in a large global trial against multiple variants which will give health officials another weapon to tackle the virus.
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72 per cent in the United States, to 66 per cent in Latin America and just 57 per cent in South Africa, from where a worrying variant has spread.
A high bar has been set by two authorised vaccines from Pfizer/BioNTech and Moderna, which were around 95 per cent effective in preventing symptomatic illness in pivotal trials when given in two doses.
Those trials, however, were conducted mainly in the United States and before new variants emerged.
The top US infectious disease specialist Anthony Fauci said the variations in effectiveness around the world underlined the need to vaccinate as many people as quickly as possible to prevent new variants from emerging.
“It’s really a wake up call for us to be nimble and to be able to adjust as this virus will continue for certain to evolve,” Dr Fauci said.
Johson & Johson's (J&J) main goal was the prevention of moderate to severe COVID-19, and the vaccine was 85 per cent effective in stopping severe disease and preventing hospitalisation across all geographies and against multiple variants 28 days after immunisation.
Dr Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases. Source: AAP
That “will potentially protect hundreds of millions of people from serious and fatal outcomes of COVID-19,” Paul Stoffels, J&J’s chief scientific officer, said of the results, which were based on 468 symptomatic cases.
Seeking approval
J&J plans to seek emergency use authorisation from the US Food and Drug Administration next week. It has said it plans to deliver one billion doses in 2021 and will produce the vaccine in the United States, Europe, South Africa and India.
Public health officials are counting on the J&J vaccine to increase much-needed supply and simplify immunisation in the United States, which has a deal to buy 100 million doses of J&J’s vaccine and an option for an additional 200 million.
J&J said the vaccine would be ready immediately upon emergency approval, but Mr Stoffels declined to say how many doses.
“Right now, any protection and additional vaccine is great. The key is not only overall efficacy but specifically efficacy against severe disease, hospitalization, and death,” Walid Gellad, a health policy associate professor at the University of Pittsburgh, said.
Michael Breen, Director of Infectious Diseases and Ophthalmology at research firm GlobalData said most countries are still desperate to get their hands on doses, regardless of whether or not the vaccine is considered highly effective.
"Moderately effective will do just fine for now," he said.
None of the vaccine recipients in the J&J trial died from COVID-19, compared with five in the placebo group, the National Institutes of Health said. Three deaths in the vaccine group overall, but none were determined to be from the virus. That compares with 16 deaths overall in the placebo arm, it added.
Unlike the Pfizer and Moderna vaccines, J&J’s does not require a second shot weeks after the first or need to be kept frozen, making it a strong candidate for use in parts of the world where transportation and cold storage are an issue.
South African variant
Several studies have emerged this month showing that a South African variant has mutated in areas of the virus that are key targets of vaccines, reducing their efficacy.
“What we are learning is there is different efficacy in different parts of the world,” Mr Stoffels told Reuters.
In a sub-study of 6,000 volunteers in South Africa, Stoffels said, the J&J vaccine was 89 per cent effective at preventing severe disease. In the South Africa portion of the trial, 95 per cent of cases were infections with the South African variant.
“I am overwhelmed by the fact that this vaccine protected against severe disease even in South Africa,” said Glenda Gray, the joint lead investigator of the South African vaccine trial.
Dr Gray, who is the chief executive of the South African Medical Research Council, said this is by far the best vaccine for South Africa to fight the mutant strain and can prevent a large number of hospitalisations and deaths.
A mid-stage trial of a N, proving to be 60 per cent effective among volunteers who didn’t have HIV. In a separate, late-stage trial in Britain it was 89.3 per cent effective.
In the J&J trial, which was conducted in eight countries, 44 per cent of participants were from the United States, 41 per cent from Central and South America and 15 per cent from South Africa. Slightly more than a third of the volunteers were over 60.
J&J’s vaccine uses a common cold virus to introduce coronavirus proteins into cells in the body and trigger an immune response, whereas the Pfizer/BioNTech and Moderna vaccines use a new technology called messenger RNA (mRNA).
